Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$27.44
+0.0%		$30.86
$13.74
▼
$65.30
$6.42B2.4210.39 million shs7.07 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$43.03
-2.2%		$47.49
$35.12
▼
$64.16
$192.31B0.7410.23 million shs11.00 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-0.29%-0.78%-8.00%+2.21%-42.69%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.33%-7.63%-7.49%-1.97%-20.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$27.44
+0.0%		$30.86
$13.74
▼
$65.30
$6.42B2.4210.39 million shs7.07 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$43.03
-2.2%		$47.49
$35.12
▼
$64.16
$192.31B0.7410.23 million shs11.00 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-0.29%-0.78%-8.00%+2.21%-42.69%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.33%-7.63%-7.49%-1.97%-20.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.13
Hold$32.4318.18% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.16
Hold$64.9450.90% Upside

Current Analyst Ratings Breakdown

Latest NVO and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$32.00
9/10/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/27/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
8/24/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$27.00 ➝ $32.00
8/21/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$39.00 ➝ $35.00
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$47.00
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$25.00 ➝ $26.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$25.00 ➝ $30.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$21.00 ➝ $28.00
8/11/2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$35.00 ➝ $33.00
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$2.35B2.73$0.83 per share32.87$2.38 per share11.53
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.11$4.68 per share9.19$6.58 per share6.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$128.37M-$0.63N/A57.17N/A-5.51%-6.51%-1.20%11/9/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0910.5212.581.4535.36%61.20%21.49%11/4/2026 (Estimated)

Latest NVO and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.0498-$0.37-$0.3202-$0.37$698.90 million$753.21 million
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.91%+21.74%20.05%N/A

Latest NVO and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
4.21
0.93
0.87
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
11.76%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2,442233.31 million205.88 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test
September 12 at 3:11 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/novo-nordisk-nvos-pediatric-obesity-opportunity-faces-a-bigger-test-1835772/
Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test
September 12 at 2:59 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-nvo-pediatric-obesity-171917899.html
Novo Nordisk A/S $NVO Shares Sold by Allworth Financial LP
September 12 at 3:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novo-nordisk-as-nvo-shares-sold-by-allworth-financial-lp-2026-09-12/
Smith Chas P & Associates PA Cpas Buys 148,565 Shares of Novo Nordisk A/S $NVO
September 11 at 7:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-smith-chas-p-associates-pa-cpas-buys-148565-shares-of-novo-nordisk-as-nvo-2026-09-11/
Novo Nordisk falls as Morgan Stanley cuts rating to Underweight on semaglutide concern
September 11 at 6:50 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4641996-novo-nordisk-falls-as-morgan-stanley-cuts-rating-to-underweight-on-semaglutide-concern
4 stocks to watch on Friday: KR, NVO, AVGO, and SPCX
September 11 at 1:49 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4642027-4-stocks-to-watch-oon-friday-kr-nvo-avgo-and-spcx
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
September 11 at 1:49 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-stock-falls-morgan-151227582.html
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
September 11 at 1:49 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-plunges-morgan-153432328.html
Could This New Opportunity Be Worth Billions for Novo Nordisk?
September 11 at 1:49 PM  |  fool.comhttps://www.fool.com/investing/2026/09/11/could-this-new-opportunity-be-worth-billions-for-novo-nordisk/
Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade
September 11 at 11:00 AM  |  youtube.comY
Novo Nordisk (NVO) Stock Drops After Morgan Stanley Downgrade on Patent Cliff Concerns
September 11 at 8:49 AM  |  blockonomi.comhttps://blockonomi.com/novo-nordisk-nvo-stock-drops-after-morgan-stanley-downgrade-on-patent-cliff-concerns/
NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity
September 11 at 8:49 AM  |  stocktwits.comS
Here Are Friday’s Top Wall Street Analyst Research Calls: Atmos Energy, Celanese, Check Point Software, Chewy, Dell Technologies, Fortinet, Global Payments, HP, Shopify, and More
September 11 at 8:49 AM  |  247wallst.comhttps://247wallst.com/investing/2026/09/11/here-are-fridays-top-wall-street-analyst-research-calls-atmos-energy-celanese-check-point-software-chewy-dell-technologies-fortinet-global-payments-hp-shopify-and-more/
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
September 10 at 6:46 PM  |  zacks.comhttps://www.zacks.com/stock/news/2988009/novo-nordisk-nvo-suffers-a-larger-drop-than-the-general-market-key-insights?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-2988009
Novo Stays Flat as Wegovy Wins China's First GLP-1 MASH Label
September 10 at 6:20 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-stays-flat-wegovy-wins-181345665.html
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
September 10 at 6:20 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-nvo-suffers-larger-214504885.html
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety
September 10 at 4:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4945061-novo-nordisk-stock-valuation-reflects-high-risk-solid-margin-of-safety
Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment
September 10 at 8:14 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-apos-semaglutide-injection-093510182.html
Novo Nordisk says Wegovy approved in China for liver disease MASH
September 10 at 4:09 AM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-wegovy-approved-china-liver-disease-mash-2026-09-10/
HSBC raises the price target for Novo Nordisk to 320 Danish kroner (300), reiterates hold - BN
September 9 at 12:58 AM  |  marketscreener.comM
Novo Nordisk's September Tightrope: A Cardiology Setback, a Paediatric Milestone, and a Buyback That Keeps Running
September 9 at 7:56 PM  |  ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Illustration of an upward-trending stock chart line overlaid on a city skyline of office towers at sunset.
Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
By Nathan Reiff | August 30, 2026
Illustration showing Hims & Hers logo and app connected through a security checkpoint icon to the Visa logo and card.
Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
By Jeffrey Neal Johnson | August 24, 2026
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$27.44 +0.00 (+0.01%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$27.48 +0.04 (+0.13%)
As of 09/11/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$43.03 -0.98 (-2.22%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$43.06 +0.02 (+0.05%)
As of 09/11/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas